Buscar
01/09/2025
Sex-related differences in the efficacy and toxicity of cancer treatments
Bertrán, AS, Rodríguez, JAM, Cardeña-Gutiérrez, A, Martinez-Callejo, V, Higuera, O, Bernardez, B, Moreno-Martínez, ME, Majem, M. Sex-related differences in the efficacy and toxicity of cancer treatments. Clinical & Translational Oncology. 2025; 27(9)DOI:10.1007/s12094-025-03893-2. PMID:40153220. IF:2.500(Q3/6D).
01/09/2025
[Translated article] Map of the residency rotations for hospital pharmacy residents in Spain
Aguilar, CC, Negro-Vega, E, Gamarra-Martínez, EFD, Castro, BM, Abánades, MP, Capafons, SR, Conde, CPM. [Translated article] Map of the residency rotations for hospital pharmacy residents in Spain. Farmacia Hospitalaria. 2025; 49(5)DOI:10.1016/j.farma.2025.06.010. PMID:40640013. IF:(Q/D).
01/09/2025
Ten-Year Experience in the Joint Dermatology-Rheumatology Approach to Patients With Psoriatic Arthritis
Ferrer, AL, Macias, HC, Sanz, LP, Alonso, AL. Ten-Year Experience in the Joint Dermatology-Rheumatology Approach to Patients With Psoriatic Arthritis. Actas Dermo-Sifiliograficas. 2025; 116(8)DOI:10.1016/j.ad.2025.06.013. PMID:40570946. IF:(Q/D).
01/09/2025
Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023
Puig, L, Sewerin, P, Schuster, C, Ng, KJ, Papadimitropoulos, M, Gadagamma, S, Nuñez, M, Lampropoulou, A. Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023. ADVANCES IN THERAPY. 2025; 42(9)DOI:10.1007/s12325-025-03258-9. PMID:40676380. IF:4.000(Q1/3D).
01/09/2025
Patient Perspectives on the Impact of Living With Hidradenitis Suppurativa: Results From the Global 'HS Uncovered' Burden of Disease Survey
Kokolakis, G, Vilarrasa, E, Garg, A, Alarcon, I, Go, M, Newbold, G, Mamareli, A, Richardson, C, McGrath, BM, Guillem, P. Patient Perspectives on the Impact of Living With Hidradenitis Suppurativa: Results From the Global 'HS Uncovered' Burden of Disease Survey. Jeadv Clinical Practice. 2025; 4(4)DOI:10.1002/jvc2.70071. PMID:. IF:(Q/D).
01/09/2025
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results
Papp, KA, Lebwohl, MG, Puig, L, Ohtsuki, M, Beissert, S, Gooderham, M, Amin, AZ, Wu, TS, Rubant, S, Bialik, B, Ashley, D, Soliman, AM, Chen, MM, Blauvelt, A. Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2025; 26(5)DOI:10.1007/s40257-025-00964-6. PMID:40728772. IF:8.800(Q1/1D).
01/09/2025
Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice
Butrón-Bris, B, Llamas-Velasco, M, Armesto, S, Sahuquillo-Torralba, A, Pujol-Montcusi, J, Ruiz-Villaverde, R, Martinez-López, A, de la Cueva, P, Romero-Mate, A, Roustan, G, Vilarrasa-Rull, E, Ferrán-Farres, M, Ovejero-Benito, MC, Palomar-Moreno, C, Navares, M, Novalbos, J, Abad-Santos, F, Dauden, E, de la Fuente, H. Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice. Actas Dermo-Sifiliograficas. 2025; 116(8)DOI:10.1016/j.ad.2025.03.030. PMID:40246146. IF:(Q/D).
01/09/2025
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
Blauvelt, A, Langley, RG, Lebwohl, M, Strober, B, Warren, RB, Puig, L, Morita, A, Gordon, KB, Fernandez-Peña, P, Kavanagh, S, Pinto, JML, Lambert, J, Hoepken, B, Deherder, D, Cross, N, Thaçi, D. Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:10.1016/j.jaad.2025.04.038. PMID:40286813. IF:11.800(Q1/1D).